CoChat

Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

Open access
Henry, James R., Kaufman, Michael D., Peng, Sheng-Bin, Ahn, Yu Mi, Caldwell, Timothy M., Vogeti, Lakshminarayana, Telikepalli, Hanumaiah, Lu, Wei-Ping, Hood, Molly M., Rutkoski, Thomas J., Smith, Bryan D., Vogeti, Subha, Miller, David, Wise, Scott C., Chun, Lawrence, Zhang, Xiaoyi, Zhang, Youyan, Kays, Lisa, Hipskind, Philip A., Wrobleski, Aaron D., Lobb, Karen L., Clay, Julia M., Cohen, Jeffrey D., Walgren, Jennie L., McCann, Denis, Patel, Phenil, Clawson, David K., Guo, Sherry, Manglicmot, Danalyn, Groshong, Chris, Logan, Cheyenne, Starling, James J., Flynn, Daniel L. · 2015 · Journal of Medicinal Chemistry
Cited by 84

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficacy in melanoma patients harboring this mutation. Because of paradoxical pathway activation, both agents were demonstrated to promote growth and metastasis of tumor cells with RAS mutations in preclinical models and are contraindicated for treatment of cancer patients with BRAF WT background, including patients with KRAS or NRAS mutations. In order to eliminate the issues associated with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with RAS mutant cancers, we sought to identify a compound not only active against BRAF V600E but also wild type BRAF and CRAF. On the basis of its superior in vitro and in vivo profile, compound 13 was selected for further development and is currently being evaluated in phase I clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.5b00067

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 84

Metadata

Authors
Henry, J. R., Kaufman, M. D., Peng, S.-B., Ahn, Y. M., Caldwell, T. M., Vogeti, L., Telikepalli, H., Lu, W.-P., Hood, M. M., Rutkoski, T. J., Smith, B. D., Vogeti, S., Miller, D., Wise, S. C., Chun, L., Zhang, X., Zhang, Y., Kays, L., Hipskind, P. A., Wrobleski, A. D., Lobb, K. L., Clay, J. M., Cohen, J. D., Walgren, J. L., McCann, D., Patel, P., Clawson, D. K., Guo, S., Manglicmot, D., Groshong, C., Logan, C., Starling, J. J., & Flynn, D. L.
Venue
Journal of Medicinal Chemistry
Published
2015-05-12
Volume
58
Issue
10
Pages
4165-4179
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W229815988
Cited by
84
References
5
FWCI
4.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells. https://app.cochat.ai/papers/10.1021/acs.jmedchem.5b00067
The paper
Henry, J. R., Kaufman, M. D., Peng, S.-B., Ahn, Y. M., Caldwell, T. M., Vogeti, L., Telikepalli, H., Lu, W.-P., Hood, M. M., Rutkoski, T. J., Smith, B. D., Vogeti, S., Miller, D., Wise, S. C., Chun, L., Zhang, X., Zhang, Y., Kays, L., Hipskind, P. A., . . . Flynn, D. L. (2015). Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5b00067

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.